Fatty Liver Disease (MASLD/NAFLD) — Management Guideline
Source: AASLD Practice Guidance on the Clinical Assessment and Management of NAFLD, 2023 (updated November 2025)
Guideline: Strong
Guideline: Conditional
Guideline: Not recommended
ClinicoQ pathway suggestion (not from the cited guideline)
Diagnosis
Diagnostic criteria
Suspected in patients with hepatic steatosis on imaging plus at least one cardiometabolic risk factor, in the absence of significant alcohol use or other causes of liver disease.
⚠ Alarm features (investigate before diagnosing)
- Signs of decompensated cirrhosis (ascites, jaundice, encephalopathy, variceal bleeding)
- Significant unexplained weight loss
- Markedly abnormal liver enzymes suggesting an alternative diagnosis
Initial workup
| Test | When to order |
|---|---|
| Liver ultrasound | Initial imaging to confirm hepatic steatosis. |
| FIB-4 score | In all patients with suspected MASLD/NAFLD, to risk-stratify for advanced fibrosis. |
| Elastography (FibroScan/VCTE) or ELF test | Indeterminate or high-risk FIB-4 score. |
| Referral to hepatology | High-risk fibrosis markers or indeterminate results requiring further workup. |
Treatment
All patients
1
Lifestyle modification (weight loss, dietary change)
Strong (Guideline recommendation) — cornerstone first-line intervention
- Dose
- Target 7–10% body weight loss
- Duration
- Ongoing
- Evidence level
- High
- Avoid if
- —
- If no response ClinicoQ pathway
- Consider pharmacologic therapy if biopsy-proven MASH or high fibrosis risk
Biopsy-proven MASH with type 2 diabetes
1
Pioglitazone
Strong (Guideline recommendation)
- Dose
- 30–45 mg once daily
- Duration
- Ongoing, reassess with follow-up liver enzymes/imaging
- Evidence level
- Moderate
- Avoid if
- Heart failure; active bladder cancer; significant fluid retention
- If no response ClinicoQ pathway
- Consider a GLP-1 receptor agonist instead of or in combination
2
GLP-1 receptor agonist (e.g., semaglutide)
Strong (Guideline recommendation) — recommended regardless of diabetes status when MASH is biopsy-confirmed
- Dose
- Per product labeling, with dose titration
- Duration
- Ongoing
- Evidence level
- Moderate-High
- Avoid if
- Personal/family history of medullary thyroid carcinoma; history of pancreatitis
- If no response ClinicoQ pathway
- Refer to hepatology for advanced therapy options
Biopsy-proven NASH, non-diabetic
1
Vitamin E
Conditional (Guideline recommendation) — for non-diabetic patients only
- Dose
- 800 IU daily
- Duration
- Ongoing, reassess with follow-up biopsy or noninvasive markers
- Evidence level
- Moderate
- Avoid if
- History of hemorrhagic stroke; caution with long-term high-dose use
- If no response ClinicoQ pathway
- Refer to hepatology for further evaluation
⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.